Profile: Discovery Laboratories Inc (DSCO.O)

DSCO.O on Consolidated Issue listed on NASDAQ Capital Market

1.59USD
28 Jul 2014
Price Change (% chg)

$-0.01 (-0.62%)
Prev Close
$1.60
Open
$1.60
Day's High
$1.61
Day's Low
$1.56
Volume
252,694
Avg. Vol
327,789
52-wk High
$3.05
52-wk Low
$1.51

Search Stocks

Discovery Laboratories, Inc., incorporated on May 18, 1993, is a specialty biotechnology company focused on creating life-saving products for critical-care patients with respiratory disease and improving the standard of care in pulmonary medicine. Its drug technology produces a synthetic, peptide-containing surfactant (KL 4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival. It is developing KL 4 surfactant in liquid, lyophilized and aerosolized dosage forms and is developing novel drug delivery technologies to enable delivery of its aerosolized KL 4 surfactant. Its first KL4 surfactant drug product, SURFAXIN (lucinactant), is approved by the United States Food and Drug Administration for the prevention of respiratory distress syndrome (RDS) in premature infants. AEROSURF is an investigational combination drug/device product that combines KL4 surfactant with the Company’s capillary aerosol generator.

AEROSURF is an investigational combination drug/device product that combines its KL4 surfactant with its capillary aerosol generator (CAG). With AEROSURF, neonatologists are being able to administer aerosolized KL 4 surfactant to premature infants supported with nCPAP, without having to use invasive intubation and mechanical ventilation. By enabling delivery of its KL 4 surfactant using less invasive procedures. The Company has developed a disposable aerosol-conducting airway connector for infants that is intended to simplify the delivery of aerosolized medications (including its aerosolized KL4 surfactant) and other inhaled therapies to critical-care patients requiring ventilatory support. This device introduces aerosolized medications directly at the patient interface and minimizes the number of connections in the ventilator circuit.

The Company competes with Chiesi Farmaceutici S.p.A., Cornerstone Therapeutics Inc., Abbott Nutritionals, Inc. and ONY, Inc.

Company Address

Discovery Laboratories Inc

Suite 100, 2600 Kelly Road
WARRINGTON   PA   18976-3622
P: +1215.4889300
F: +1215.4889301

Company Web Links

Search Stocks